VREO.CX Quote, Financials, Valuation and Earnings

Fennec Pharmaceuticals, Inc. has a net margin of -19.49% compared to Vireo Growth, Inc.'s net margin of -37.34%. Vireo Growth, Inc.'s return on equity of -36.88% beat Fennec Pharmaceuticals, Inc.'s return on equity of -460.92%.

Vireo Growth, Inc. has a consensus price target of --, signalling upside risk potential of 16.07%. On the other hand Fennec Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Vireo Growth, Inc. has higher upside potential than Fennec Pharmaceuticals, Inc., analysts believe Vireo Growth, Inc. is more attractive than Fennec Pharmaceuticals, Inc..

Vireo Growth, Inc. has a beta of -0.004, which suggesting that the stock is 100.363% less volatile than S&P 500. In comparison Fennec Pharmaceuticals, Inc. has a beta of 1.605, suggesting its more volatile than the S&P 500 by 60.515%.

Vireo Growth, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fennec Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vireo Growth, Inc. pays -- of its earnings as a dividend. Fennec Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Vireo Growth, Inc. quarterly revenues are $145.7M, which are larger than Fennec Pharmaceuticals, Inc. quarterly revenues of $19.2M. Vireo Growth, Inc.'s net income of -$28.4M is lower than Fennec Pharmaceuticals, Inc.'s net income of -$7.2M. Notably, Vireo Growth, Inc.'s price-to-earnings ratio is -- while Fennec Pharmaceuticals, Inc.'s PE ratio is 150.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vireo Growth, Inc. is 1.14x versus 4.35x for Fennec Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Green Thumb Industries, Inc. has a net margin of -19.49% compared to Vireo Growth, Inc.'s net margin of 26.72%. Vireo Growth, Inc.'s return on equity of -36.88% beat Green Thumb Industries, Inc.'s return on equity of 6.32%.

Vireo Growth, Inc. has a consensus price target of --, signalling upside risk potential of 16.07%. On the other hand Green Thumb Industries, Inc. has an analysts' consensus of $19.24 which suggests that it could grow by 111.42%. Given that Green Thumb Industries, Inc. has higher upside potential than Vireo Growth, Inc., analysts believe Green Thumb Industries, Inc. is more attractive than Vireo Growth, Inc..

Vireo Growth, Inc. has a beta of -0.004, which suggesting that the stock is 100.363% less volatile than S&P 500. In comparison Green Thumb Industries, Inc. has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.516%.

Vireo Growth, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Green Thumb Industries, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vireo Growth, Inc. pays -- of its earnings as a dividend. Green Thumb Industries, Inc. pays out -- of its earnings as a dividend.

Vireo Growth, Inc. quarterly revenues are $145.7M, which are smaller than Green Thumb Industries, Inc. quarterly revenues of $433.8M. Vireo Growth, Inc.'s net income of -$28.4M is lower than Green Thumb Industries, Inc.'s net income of $115.9M. Notably, Vireo Growth, Inc.'s price-to-earnings ratio is -- while Green Thumb Industries, Inc.'s PE ratio is 13.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vireo Growth, Inc. is 1.14x versus 1.34x for Green Thumb Industries, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sharp Therapeutics Corp. has a net margin of -19.49% compared to Vireo Growth, Inc.'s net margin of --. Vireo Growth, Inc.'s return on equity of -36.88% beat Sharp Therapeutics Corp.'s return on equity of --.

Vireo Growth, Inc. has a consensus price target of --, signalling upside risk potential of 16.07%. On the other hand Sharp Therapeutics Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Vireo Growth, Inc. has higher upside potential than Sharp Therapeutics Corp., analysts believe Vireo Growth, Inc. is more attractive than Sharp Therapeutics Corp..

Vireo Growth, Inc. has a beta of -0.004, which suggesting that the stock is 100.363% less volatile than S&P 500. In comparison Sharp Therapeutics Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vireo Growth, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sharp Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vireo Growth, Inc. pays -- of its earnings as a dividend. Sharp Therapeutics Corp. pays out -- of its earnings as a dividend.

Vireo Growth, Inc. quarterly revenues are $145.7M, which are larger than Sharp Therapeutics Corp. quarterly revenues of --. Vireo Growth, Inc.'s net income of -$28.4M is lower than Sharp Therapeutics Corp.'s net income of -$4.7M. Notably, Vireo Growth, Inc.'s price-to-earnings ratio is -- while Sharp Therapeutics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vireo Growth, Inc. is 1.14x versus -- for Sharp Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Wesana Health Holdings has a net margin of -19.49% compared to Vireo Growth, Inc.'s net margin of --. Vireo Growth, Inc.'s return on equity of -36.88% beat Wesana Health Holdings's return on equity of --.

Vireo Growth, Inc. has a consensus price target of --, signalling upside risk potential of 16.07%. On the other hand Wesana Health Holdings has an analysts' consensus of -- which suggests that it could grow by 2383.25%. Given that Wesana Health Holdings has higher upside potential than Vireo Growth, Inc., analysts believe Wesana Health Holdings is more attractive than Vireo Growth, Inc..

Vireo Growth, Inc. has a beta of -0.004, which suggesting that the stock is 100.363% less volatile than S&P 500. In comparison Wesana Health Holdings has a beta of -1.000, suggesting its less volatile than the S&P 500 by 200.004%.

Vireo Growth, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Wesana Health Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vireo Growth, Inc. pays -- of its earnings as a dividend. Wesana Health Holdings pays out -- of its earnings as a dividend.

Vireo Growth, Inc. quarterly revenues are $145.7M, which are larger than Wesana Health Holdings quarterly revenues of --. Vireo Growth, Inc.'s net income of -$28.4M is higher than Wesana Health Holdings's net income of --. Notably, Vireo Growth, Inc.'s price-to-earnings ratio is -- while Wesana Health Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vireo Growth, Inc. is 1.14x versus 0.39x for Wesana Health Holdings. Usually stocks with elevated PS ratios are considered overvalued.